Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reduced-dose PCd in Relapsed-Refractory Multiple Myeloma
NCT06255847Phase 2Recruiting
- Sponsor
- Shanxi Bethune Hospital
- Start
- Jun 2022
- Primary completion
- Jun 2025
- Modality
- Molecular Glues
- Countries
- 1
01
Overview
A Phase 2 trial of pomalidomide in multiple myeloma (MM), sponsored by Shanxi Bethune Hospital. Started Jun 2022; status: recruiting.
02
Drugs
pomalidomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT06255847.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06255847.